Reistone Biopharma | Press Release

Press Release

Positive Phase 2 Results for Reistone’s JAK Inhibitor Demonstrate Significant Improvement in Patients with Moderate-to-Severe Ulcerative Colitis

SHANGHAI, Jan. 20, 2021—Reistone Biopharma Co. Ltd. (“Reistone”), a clinical stage biopharmaceutical company focused on developing novel medicines for immuno-inflammatory, diseases with high unmet medical needs, today announced that SHR0302, an investigat

2021-02-04 Learn more
Reistone Biopharma Announces Positive Topline Results from Phase 2 Clinical Trial Evaluating SHR0302, a JAK1 Inhibitor for the Treatment of Moderate-to-Severe Atopic Dermatitis

SHANGHAI, Oct. 26, 2020 /PRNewswire/ -- Reistone Biopharma Co. Ltd. ("Reistone"), an innovative clinical stage biopharmaceutical company focused on developing novel medicines for immuno-inflammatory diseases with high unmet medical needs, today announced

2020-10-27 Learn more
Highly Selective JAK1 Inhibitor / New Drug SHR0302 Base Ointment of Reistone Biopharma Having Been Approved for Clinical Trial to Treat Vitiligo

Recently, Reistone Biopharma Company Limited received the Notice of Clinical Trial approved and issued by NMPA, and was approved to carry out the clinical trial of SHR0302 base ointment to be intended for vitiligo.

2020-10-19 Learn more